Dupixent market seen growing on allergies, chronic disease demand through 2030

The Business Research Company says Dupixent’s global market is set to expand through 2030 as chronic inflammatory diseases, rising allergy rates, and broader biologics use drive demand. North America led the market in 2025, while Asia-Pacific is expected to grow fastest during the forecast period.

Why it matters: - Dupixent’s growth reflects rising demand for targeted biologics in chronic inflammatory diseases with large unmet need. - The market expansion could affect treatment access for patients with atopic dermatitis, asthma, and other inflammatory conditions. - Broader reimbursement and specialty pharmacy networks could make the drug easier to adopt across more markets.

What happened: - The Business Research Company released an analysis of the Dupixent global market, covering market size, trends, and forecasts for 2026-2035. - The report says the Dupixent market gained value historically because of high rates of atopic dermatitis and asthma, regulatory approvals across multiple indications, specialist adoption, and better patient outcomes. - The report projects growth through the forecast period as use expands in more inflammatory conditions and demand for biologics increases. - North America held the largest share of the Dupixent market in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - Dupixent is a prescription monoclonal antibody used for chronic inflammatory illnesses, mainly in patients with moderate to severe disease. - The drug blocks interleukin-4 and interleukin-13, which are key drivers of inflammation and allergic reactions. - Dupixent is delivered by injection, either subcutaneously or with a pre-filled pen device. - The report links rising skin allergy cases to market demand. - An October 2023 European Academy of Dermatology and Venereology survey of 44,689 adults across 27 European countries found that 43% of EU citizens had experienced at least one skin condition in the prior year. - The survey cited common conditions including fungal infections, atopic dermatitis, alopecia and acne. - The report says healthcare spending is also supporting market growth by encouraging innovation in biologics and wider use of advanced therapies. - UK healthcare spending reached about $306 billion (£292 billion) in 2023, up 5.6% nominally from 2022, compared with 0.9% growth in 2022. - The geographic analysis covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report’s 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology and future trend analysis, and updated graphics and tables. - The company offers a free sample report and the full Dupixent market report here and here.

Between the lines: - The report points to a shift toward more long-term maintenance use and more selective biologic therapies. - Growing patient preference for injectable biologics suggests convenience and familiarity may help support adoption. - The market outlook appears tied not just to disease prevalence, but also to payor coverage and care delivery infrastructure.

What's next: - The report expects Dupixent demand to keep rising as allergy rates, asthma cases and other inflammatory conditions increase. - Wider reimbursement policies and specialty pharmacy growth could shape how quickly the drug expands in new indications. - Future market gains will likely depend on how quickly providers and health systems adopt targeted biologic treatment pathways. - The forecast period runs through 2035, with the market analysis highlighting 2030 as a key growth window.